tirzepatide shortage 2025 The GLP-1 drug is over. What's next for the compounders? - Pharma Technology Focus | Issue 154 New project announcement: HHS‑OIG is

JNL: Jun NH2-terminal kinase

Initial research suggests that GLP-1 receptor agonists may help protect against neurodegenerative diseases such as Alzheimers

They may be especially helpful for patients managing type 2 diabetes with milder goals or for those who are needle averse

Keep in mind, if you have a family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), your provider may advise against GLP-1 therapy as a precaution

Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow eligible Medicare Part D patients to access certain obesity-indicated GLP-1 medications, including Foundayo, Wegovy, and certain Zepbound formulations, for no more than $50 per month through December 31, 2027

Nov 11 2021;9(11)doi:10.3390/toxics9110299